ELTX - Company ID 0001601485
The table below shows Elicio Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $6.76M | $5.04M | $7.01M | $7.78M | $7.21M | $8.18M |
| SG&A |
Elicio Therapeutics, Inc. reported annual revenue of $2.30M for fiscal year 2022. That is down 91.9% from $28.31M in fiscal 2021. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $3.85M |
| $3.01M |
| $3.08M |
| $2.96M |
| $3.14M |
| $2.74M |
| Operating income | -$10.60M | -$8.04M | -$10.09M | -$10.74M | -$10.34M | -$10.92M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$11.82M | -$10.08M | -$10.56M | -$11.21M | -$18.84M | -$7.23M |
| EPS (diluted) | -$0.65 | -$0.60 | -$0.66 | -$0.87 | -$1.39 | -$0.64 |